Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects

Summary

This is Phase 2, open label, multi-center study to assess safety and efficacy of vactosertib in combination with pembrolizumab as 1st line treatment for subjects with advanced or metastatic, PD-L1 positive, non-small cell lung cancer (NSCLC) who have not previously received systemic therapy for advanced disease and in whom EGFR, ALK, BRAF, ROS1-directed therapy is not indicated.

Timeline

Start

2020-12-17

Primary completion

2024-08-05

Completion

2024-08-05

Outcome

Outcome not reported

Stopped (Business): “This is because Medpacto decided to modify its development strategy as the business and development environment changed.”

Drugs

Indications